Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
New England Journal of Medicine
•
June 13, 2026
Talquetamab combinations delay myeloma progression
Talquetamab plus daratumumab, with or without pomalidomide, improved progression-free survival versus standard triplet therapy. *Randomized controlled trial; Level 2 (OCEBM).
- Level of evidence
- Level 2 (OCEBM)
- DocG quality score
- 7.7 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
